|
| |
| | | 68490 | | 14.06.2021 | | Bristol-Myers Squibb SA | | | | | | | | | | | | | 07.16.10. | | | | 07.16.40. | | IPro |
| | Seq.-nr. | Préparation | Description | Forme galénique | Classe d'ATC | |
|---|
| 01 | Lenalidomid BMS 2,5 mg | Hartkapseln | Capsules (Lenalidomidum 2.5 mg) | L04AX04 | IPat | | 02 | Lenalidomid BMS 5 mg | Hartkapseln | Capsules (Lenalidomidum 5 mg) | L04AX04 | | | 03 | Lenalidomid BMS 7,5 mg | Hartkapseln | Capsules (Lenalidomidum 7.5 mg) | L04AX04 | | | 04 | Lenalidomid BMS 10 mg | Hartkapseln | Capsules (Lenalidomidum 10 mg) | L04AX04 | | | 05 | Lenalidomid BMS 15 mg | Hartkapseln | Capsules (Lenalidomidum 15 mg) | L04AX04 | | | 06 | Lenalidomid BMS 20 mg | Hartkapseln | Capsules (Lenalidomidum 20 mg) | L04AX04 | | | 07 | Lenalidomid BMS 25 mg | Hartkapseln | Capsules (Lenalidomidum 25 mg) | L04AX04 | |
|
|
|
